Advanced Biomed Inc. Common Stock (ADVB) 10-Year Financial Performance & Capital Metrics

ADVB • • Industrial / General

HealthcareDiagnostics & ResearchCancer Diagnostics & Oncology TestingLiquid Biopsy & Circulating Tumor DNA

AboutAdvanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, a fully automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cells (CTCs) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also provides microfluidic biochips comprising A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips that are designed to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include the A+CTCE kit, which is used to identify epithelial circulating tumor cells and is determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; the A+CTCM kit, which is used to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; the A+EMT, which is used to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and the A+CM, which is used to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.Show more

Revenue $0
EBITDA -$83K +96.1%
Net Income -$102K +96.4%
EPS (Diluted) -0.00 +96.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -0.01% +100.0%
ROIC -0.02%
Debt/Equity 0.00 -99.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 8 (bottom 8%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-2.24%

EPS CAGR

10Y-

5Y-

3Y-

TTM-2.02%

ROCE

10Y Avg-115.41%

5Y Avg-115.41%

3Y Avg-96.07%

Latest-0.01%

Peer Comparison

Liquid Biopsy & Circulating Tumor DNA

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BIAFbioAffinity Technologies, Inc.	6.39M	1.42	-0.06	269.75%	-217.5%	-165.57%	0.58
VNRXVolitionRx Limited	35.61M	0.29	-0.94	59.1%	-15.54%
BDSXBiodesix, Inc.	66.27M	8.33	-1.26	45.3%	-49.31%	-337.3%	2.97
GRALGRAIL, Inc.	3.8B	97.44	-1.53	34.9%	-286.43%	-18.14%	0.03
GHGuardant Health, Inc.	14.54B	111.98	-31.46	31.04%	-44.18%	-45.84%
ADVBAdvanced Biomed Inc. Common Stock	6.86M	0.32	-67.45		-135.32%	-77.48%	0.00

Profit & Loss

	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	2.03K	4.48K	11.89K	12.55K	10.71K
COGS % of Revenue	-	-	-	-	-
Gross Profit+	-2.03K	-4.48K	-11.89K	-12.55K	-10.71K
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-1.2%	-1.66%	-0.06%	0.15%
Operating Expenses+	1.84M	2.37M	3.07M	2.54M	83.4K
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	44.47K	624.77K	1.32M	1.26M	2.11B
SG&A % of Revenue	-	-	-	-	-
Research & Development	1.73M	1.62M	1.38M	880.19K	909.77M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	57.85K	130.07K	365.23K	399.6K	-3.02B
Operating Income+	-1.84M	-2.37M	-3.07M	-2.54M	-94.11K
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-0.29%	-0.29%	0.17%	0.96%
EBITDA+	-1.78M	-2.25M	-2.71M	-2.14M	-83.4K
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-0.26%	-0.2%	0.21%	0.96%
D&A (Non-Cash Add-back)	57.85K	126.63K	365.23K	399.6K	10.71K
EBIT	-1.84M	-2.37M	-3.07M	-2.54M	-101.53K
Net Interest Income+	28	243	21.4K	53.49K	776
Interest Income	28	243	21.4K	53.49K	776
Interest Expense	0	0	0	0	0
Other Income/Expense	-218	-1.65M	-661.55K	-240.71K	-7.41K
Pretax Income+	-1.84M	-4.03M	-3.73M	-2.78M	-101.52K
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-1.84M	-4.03M	-3.73M	-2.78M	-101.52K
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-1.19%	0.07%	0.25%	0.96%
Net Income (Continuing)	-1.84M	-4.03M	-3.73M	-2.78M	-101.52K
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.16	-0.28	-0.19	-0.14	-0.00
EPS Growth %	-	-0.75%	0.32%	0.26%	0.97%
EPS (Basic)	-0.16	-0.28	-0.19	-0.14	-0.00
Diluted Shares Outstanding	11.46M	14.18M	19.94M	20M	21.64M
Basic Shares Outstanding	11.46M	14.18M	19.93M	20M	21.64M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	913.5K	5.01M	2.79M	3.05M	6.03B
Cash & Short-Term Investments	65.92K	4.78M	2.62M	2.61M	2.9B
Cash Only	65.92K	4.78M	2.62M	2.61M	2.9B
Short-Term Investments	0	0	0	0	0
Accounts Receivable	419	162.52K	4.81K	6.32K	7.96K
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	-6.32K	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	0	145.14K	205.18K	3.13B
Total Non-Current Assets+	92.88K	1.71M	1.81M	1.41M	479.77M
Property, Plant & Equipment	92.88K	1.23M	954.07K	651.27K	65.4M
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	410.8K	250.32K	119K	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	0	71.02K	609.6K	638.87K	414.37M
Total Assets+	1.01M	6.71M	4.6M	4.46M	6.51B
Asset Turnover	-	-	-	-	-
Asset Growth %	-	5.67%	-0.31%	-0.03%	1459.09%
Total Current Liabilities+	28.35K	2.99M	3.28M	2.73M	2.89B
Accounts Payable	194	762.2K	632.82K	620.48K	21.66K
Days Payables Outstanding	34.86	62.14K	19.43K	18.05K	738.04
Short-Term Debt	188	7.96K	6.95K	1.92K	1.08M
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	22.73K	-11.19K	-9.7K	2.05M	2.89B
Current Ratio	32.22x	1.67x	0.85x	1.12x	2.09x
Quick Ratio	32.22x	1.67x	0.85x	1.12x	2.09x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	1.78K	232.19K	18.81K	64.53K	145.65M
Long-Term Debt	0	0	0	0	139.77K
Capital Lease Obligations	1.78K	232.19K	18.81K	64.53K	201
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	145.65M
Total Liabilities	30.13K	3.22M	3.29M	2.8M	3.03B
Total Debt+	7.21K	476.83K	242.33K	128.66K	1.26M
Net Debt	-58.71K	-4.31M	-2.38M	-2.48M	-2.9B
Debt / Equity	0.01x	0.14x	0.19x	0.08x	0.00x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-	-	-	-
Total Equity+	976.24K	3.49M	1.31M	1.66M	3.48B
Equity Growth %	-	2.58%	-0.63%	0.27%	2089.81%
Book Value per Share	0.09	0.25	0.07	0.08	160.70
Total Shareholders' Equity	976.24K	3.49M	1.31M	1.66M	3.48B
Common Stock	14.72K	99K	20K	20K	21.64M
Retained Earnings	-5.43M	-9.46M	-13.19M	-15.97M	-19.23B
Treasury Stock	0	0	0	0	0
Accumulated OCI	-177.09K	268.86K	804.02K	1.12M	1.34B
Minority Interest	0	0	0	0	0

Cash Flow

	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-473.98K	-741.45K	-2.96M	-2.13M	-181.46K
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-0.56%	-3%	0.28%	0.91%
Net Income	-1.84M	-4.03M	-3.73M	-2.78M	-3.26B
Depreciation & Amortization	57.85K	126.63K	365.23K	399.6K	343.83M
Stock-Based Compensation	0	0	0	0	0
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	0	1.66M	150.21K	0	2.92B
Working Capital Changes	1.31M	1.5M	253.71K	256.34K	-90.65K
Change in Receivables	28	243	21.4K	53.49K	0
Change in Inventory	0	0	0	0	0
Change in Payables	17.24K	912.42K	381.25K	479.63K	-3.67K
Cash from Investing+	-25.44K	-1.08M	-263.01K	-74.11K	-985
Capital Expenditures	-25.44K	-889.59K	-210.88K	-74.11K	-985
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	-393.62K	-1.64K	0	0
Cash from Financing+	697.16K	6.1M	458.14K	1.87M	184.87K
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	0	-553.47K	212.18K	0
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-499.42K	-2.05M	-3.18M	-2.2M	-182.45K
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-3.11%	-0.55%	0.31%	0.92%
FCF per Share	-0.04	-0.14	-0.16	-0.11	-0.01
FCF Conversion (FCF/Net Income)	0.26x	0.18x	0.79x	0.76x	1.79x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024	2025
Return on Equity (ROE)	-188.19%	-180.3%	-155.62%	-187.43%	-0.01%
Return on Invested Capital (ROIC)	-	-3488.71%	-	-	-0.02%
Debt / Equity	0.01x	0.14x	0.19x	0.08x	0.00x
FCF Conversion	0.26x	0.18x	0.79x	0.76x	1.79x

Frequently Asked Questions

Growth & Financials

Advanced Biomed Inc. Common Stock (ADVB) reported $0.0M in revenue for fiscal year 2025.

Advanced Biomed Inc. Common Stock (ADVB) grew revenue by 0.0% over the past year. Growth has been modest.

Advanced Biomed Inc. Common Stock (ADVB) reported a net loss of $2.3M for fiscal year 2025.

Dividend & Returns

Advanced Biomed Inc. Common Stock (ADVB) has a return on equity (ROE) of -0.0%. Negative ROE indicates the company is unprofitable.

Advanced Biomed Inc. Common Stock (ADVB) had negative free cash flow of $1.0M in fiscal year 2025, likely due to heavy capital investments.

← Back to Screener